Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

bioAffinity Technologies Q3 2026 Results: Net Loss of $5.28M, Loss Widens

For the nine months ended September 30, 2026, bioAffinity Technologies reported a net loss of $12.3 million on revenue of $3.9 million, compared to a net loss of $11.8 million on revenue of $4.6 million in the prior year period. The company's cash position decreased significantly to $2.6 million from $6.4 million at year-end 2025, driven by increased operating expenses in clinical development and general administration.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.11.4
Profit before tax-5.3-5.0
Net income-5.3-5.1
EPS (diluted, $ a share)$-5.89$-71.05

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-26.0%
Operating margin-328.0%
Source

10-Q filed with the SEC, NASDAQ: BIAF. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

bioAffinity Technologies, Inc.: key numbers

Share price
$2.00Close, Nov 16
Market cap
$3.64M
Shares outstanding
1.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from bioAffinity Technologies, Inc.

All →
8:04 AM ET 8-K
Business Update

bioAffinity Technologies Business Update

bioAffinity Technologies announced a record monthly testing volume for its CyPath Lung test in October 2026, with 235 tests performed. This volume represents a 29% increase over October 2025 and is equivalent to approximately 45% of the total tests performed in the entire third quarter of 2026. The company attributed the growth to expanded sales efforts and increased adoption by both new and existing physicians.

5:29 PM ET 8-K
Financial Results

bioAffinity Technologies Financial Results

bioAffinity Technologies reported its Q3 2026 financial results, highlighted by a 79% year-to-date increase in CyPath Lung testing revenue to $1.1 million. The company saw a 100% increase in test unit sales and an 89% increase in the number of ordering physicians compared to the prior year. Management noted continued momentum in commercialization and expansion of its government healthcare distribution network.

Term
Q3 2026

“Our third quarter results reflect the growing clinical adoption of CyPath® Lung as a vital tool for the early detection of lung cancer. With test unit sales doubling year-to-date and a significant increase in our physician base, we are seeing the direct impact of our commercial strategy and the clear need for noninvasive diagnostic solutions in the lung cancer care continuum.”

Maria Zannes, President and Chief Executive Officer
8:31 AM ET 8-K
Business Update

bioAffinity Technologies Business Update

bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina’s 'Battle of the Blues' event on November 5, 2026. The company will highlight its CyPath Lung noninvasive diagnostic test alongside physicians and patient advocates to promote early lung cancer detection during National Lung Cancer Awareness Month.

9:30 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its CyPath Lung test and a new investigational test for asthma and COPD-related lung inflammation. The presentation will focus on improving lung cancer risk stratification and managing pulmonary nodules using the company's noninvasive flow cytometry technology.

Counterparty
American College of Chest Physicians
9:23 AM ET 8-K
Clinical Trial Data

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its sputum-based tests for lung inflammation. The data demonstrates the ability to detect multiple protein biomarkers and biologic drug targets for asthma and COPD using the company's flow cytometry and AI platform. The research aims to support a precision medicine approach for identifying patients who could benefit from specific biologic therapies.

Counterparty
American College of Chest Physicians
4:31 PM ET 8-K
Capital Raise

bioAffinity Technologies Capital Raise of $4M

bioAffinity Technologies entered into a securities purchase agreement with an institutional investor to raise approximately $4 million in gross proceeds. The offering consists of 116,545 shares of common stock and pre-funded warrants for 536,836 shares, priced at $6.122 and $6.115 respectively, alongside a private placement of unregistered warrants.

Value
$4M
Counterparty
institutional investor

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.